UnknownNCT06608641
Efficacy and Safety of Endoxifen in Bipolarity type I Patients
Medication studyAges 18–65United States
Understand this study
Who could participate?
Listed age limits: 18 years to 65 years.
- Listed locations
- Cerritos and 11 more locationsSee all locations and recruitment
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
What to know before participating
A point to clarify
This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?
Things to check before joining
Study start dateStarted: March 19, 2024
- Recruitment status
- Unknown
- Enrollment listed in the registry
- 490
- Sponsor
- Jina Pharmaceuticals Inc.
- Sponsor type
- Other organization
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
- Locations
- United States
- Age range
- From 18 Years to 65 Years
- Official registry ID
- NCT06608641
- Official title
Show the full official title
A Double-blind, Oral, Multiple-dose, Parallel, Randomized Study to Evaluate Efficacy and Safety of Endoxifen in Bipolar I Disorder Patients With Acute Mania Episodes With or Without Mixed Features
Recruitment & locations
Status unknownThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Cerritos · Los Angeles · Orange
8 more locations
- Miami
- Miami Lakes
- Miami Springs
- Tampa
- East Point
- Norcross
- Peachtree Corners
- Flowood
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is Jina Pharmaceuticals Inc.
Does this study involve medication?
Yes. The study involves medication, including Endoxifen enteric-coated tablet (8 mg) and Placebo Tablets.
Who can participate?
Listed age limits: 18 years to 65 years.
